Pilocarpine 1.25% eye drops,
does it really help with Improved near vision for several hours after dosing in adults with presbyopia?
research showsPilocarpine 1.25% eye drops are rated C because they improve near-vision chart performance for several hours after dosing in adults with presbyopia. In the 323-participant GEMINI 1 trial, 30.7% versus 8.1% gained at least three lines of near visual acuity three hours after dosing on day 30. A difference remained at six hours, but the three-line response at eight hours was not significant. GEMINI 1 and 2 replicated the direction in about 750 participants, but both were 30-day manufacturer-development trials using a mesopic, high-contrast vision-chart endpoint. Long-term durability and meaningful improvement in everyday reading and work remain inadequately established, so the surrogate-endpoint and sponsor-evidence ceiling supports C with 56 points.
ads claimPromotion can describe clear reading without glasses or an all-day solution to presbyopia. The actual 30-day evidence concerns the proportion gaining three lines on a specified mesopic, high-contrast chart, while the key eight-hour response and durable everyday function remain unconfirmed.
Useful facts when choosing a product
- VUITY is a prescription pilocarpine hydrochloride 1.25% eye drop for adult presbyopia, dosed as one drop in each eye once daily; the label allows a second drop in each eye three to six hours after the first dose.
- When another topical eye medicine is used, doses are separated by at least five minutes; contact lenses are removed before dosing and reinserted no sooner than ten minutes later.
- Headache, eye irritation or redness, brow ache, transient blur, and dim or dark vision can occur. Driving should be avoided when vision is unclear, with particular caution for night driving and hazardous tasks in poor illumination.
- Rare retinal tears and detachments have been reported with miotics. Retinal examination is considered before treatment, and flashes, new floaters, a curtain-like field defect, or sudden vision loss require immediate eye care.
What the research actually shows
The 2022 GEMINI 1 trial by Waring and colleagues double-blindly randomized 323 adults aged 40 to 55 years with presbyopia to pilocarpine 1.25% or vehicle in both eyes once daily for 30 days. At three hours on day 30, 30.7% versus 8.1% gained at least three lines of near visual acuity. The key endpoint remained significant at six hours, but the three-line response at eight hours was not significant. The 2024 pooled analysis by Lievens and colleagues combined approximately 750 participants from identically designed GEMINI 1 and 2 and found similar short-term responses in people with and without prior LASIK or PRK. The FDA label describes once-daily use and an optional second dose based on GEMINI 1, GEMINI 2, and the 14-day VIRGO study, but authorization was not treated as evidence for a grade above C.
Why this is classified as C (56)
The 30.7% versus 8.1% three-hour responder rate in GEMINI 1 and the consistent direction in GEMINI 2 support a several-hour improvement in near-vision chart performance. Thirty-day follow-up, a nonsignificant key eight-hour response, a vision-chart surrogate, uncertain daily function and durability, and concentration in Allergan and AbbVie-sponsored evidence trigger the rules ① and ②-b ceiling of C with 56 points.
Counterpoint. For some adults who want to reduce temporary reliance on reading glasses, the drops may be practically useful. Retinal risk, activities in dim light, headache or blur, and the desired duration should be compared in eye-care consultation.
Rejudgment record. Cross-check applied — Applied the rules ① and ②-b ceiling of C because GEMINI 1 and 2 demonstrated several hours of near-vision chart improvement in 30-day randomized vehicle-controlled trials, but the endpoint is surrogate, the key eight-hour response was nonsignificant, durable daily function is uncertain, and evidence is concentrated in the Allergan and AbbVie development program
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Gain of at least three near-vision chart lines three hours after dosing | C | GEMINI 1 found 30.7% versus 8.1%, but this was a chart surrogate in a 30-day manufacturer trial. |
| Improved near vision for about six hours after dosing | C | The key six-hour secondary endpoint was positive, but the eight-hour three-line response was nonsignificant, limiting duration claims. |
| Durable improvement in everyday reading and near-work function | ? | No human trial evaluating sustained improvement in everyday near-vision function beyond 30 days was identified; only short-term vision-chart and patient-reported outcomes exist. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Waring GO IV et al. 2022 GEMINI 1 | Multicenter randomized participant- and investigator-masked vehicle-controlled phase 3 trial | 160 | Sponsored by Allergan and AbbVie; several authors were company employees | Gain of at least three lines in mesopic high-contrast binocular distance-corrected near visual acuity at three and six hours on day 30 | The three-hour response was 30.7% versus 8.1%, an absolute difference of 22.5%; six hours was also significant, but the eight-hour three-line response was not. | Pivotal short-term vision-chart randomized evidence |
| Lievens CW et al. 2024 pooled GEMINI 1 and 2 | Pooled analysis of two identically designed randomized vehicle-controlled phase 3 trials | 80 | Allergan and AbbVie development program with company employee coauthors | Time-specific gain of at least three near-vision lines on day 30 | Short-term response was similar with or without prior LASIK or PRK, and the three-hour responder rate in the prior-surgery subgroup was 37.8% versus 5.1%. | Directional replication across two trials and subgroup support |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Pilocarpine 1.25% eye drops x several hours of improved near vision in adult presbyopia — Evidence Grade C·56. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/pilocarpine-1-25-presbyopia-near-vision-hours/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.